

Panel meeting (11) 27.10.2025

Place: Teams

Present: Anna-Liisa Levonen-Harju (chair), Eero Castren, Mikko Finnilä, Eija Pirinen, Emma Raitoharju, Timo Roine, Alejandra Sierra Lopez, Pasi Tavi

Absent: Mikko Niemi, Matalena Parikka, Helder Santos, Dario Greco, Reetta Hinttala, Pasi Liljeberg, Jukka Partanen, Susanna Miettinen

Secretariat: Leena Wahlfors and Anna-Kaarina Linna

1. Opening

The Chair opened the Meeting at 9.03.

2. Announcements

- The panelists introduced themselves.
- It was noted that the scientific disciplines for which the panelists are responsible, as well as the areas of expertise of the panel members, shall be listed in Appendix 1.

3. Announcement of engagements

It was noted that the panelists must always disclose any potential conflicts of interest, especially when the panel is discussing a publication channel with which the panelist has had – or continues to have – close ties in the form of publication, editorial work, financial interest, or other influence. These ties include, at a minimum, the panelist having, within the last five years:

- published in the channel in question more than once,
- served as an editor or member of the editorial board of the channel,
- owned shares in the publishing company or a comparable organization, or
- held another position that could cause financial or interest conflicts.

Disclosure does not automatically prevent participation in decision-making, but the panel must take the ties into account in the evaluation process.

([Handbook 2025 - 2028.](#))

The point "About having published in the channel in question more than once within five years" raised discussion. It was noted that it should be brought to the steering group meeting in order to get a clarification of which actions does it require from the panels in practice.

4. The Development of JUFO Classification

The development of the Publication Forum classification is part of the Forum's long-term operational and development plan. As part of this work, the

Publication Forum Steering Group decided at its meeting on 8 September 2025 that:

A. Structure of the Classification

- In the Publication Forum (JUFO) classification, the designation “*Level 0*” will be discontinued. Instead, the category “*other identified publication channels*” will be used for scholarly publication channels that are not classified at Levels 1, 2, or 3, and that are not designated as professional or popular publication channels.
- From the beginning of 2026, evaluation panels will no longer assign publication channels to Level 3. Information on Level 3 will be removed from the JUFO portal at the beginning of 2027, when the updated classification is published.

Implementation:

- Update the website and the Panel Member’s Handbook by the end of 2025.
- Apply the necessary changes to the panel-specific Excel templates used in the evaluation update at the beginning of 2026.
- Apply the necessary changes to the publication channel database and JUFO portal by the end of 2026.

B. Classification Criteria

Changes to level 1 criteria:

- Criterion 2 (Transparency):
Current wording: “The publication channel’s website provides a transparent description of the editorial board and the peer review process. (A book publisher may meet Level 1 criteria even if the editorial board and peer review process are not described on the website.)” -> Revised wording: “The publication channel’s website provides a transparent description of the editorial board and the peer review process. This applies also to book publishers.”
- Criterion 7 (Relevance) will be divided into two separate criteria:
 - 7. Relevance: The publication channel is central from the perspective of its discipline’s international or Finnish research community.
 - 8. Thoroughness: The primary objective of the publication channel is to promote and ensure scholarly quality, and its editorial and peer review practices are careful and reliable. A [checklist](#) of practices identified as problematic may be used as a support tool in the assessment.

Changes to Level 2 criteria:

- A new (fourth) criterion will be added: The publication channel enables immediate open access (either via the service itself or through self-archiving).

- From the specific criteria for Finnish- and Swedish-language publication channels, the criterion “Research questions are strongly contextualised within Finnish society or Finnish- and Swedish-language culture” will be removed.

Implementation: Update the website and the Panel Member’s Handbook by the end of 2025.

C. Quotas and Calculation of Publication Volume

Quotas for publication series and book publishers will no longer take Level 3 into account. Consequently:

- The combined publication volume of series classified at Level 2 may amount to no more than 25% of the total publication volume of all series within the panel (Levels 1–2 combined).
- The list of book publishers is shared across all panels. Selections for Level 2 are made jointly by the panel chairs. Approximately 100 publishers across all fields may be classified at Level 2. Quotas are thus determined by the number of publishers, not by their publication output.

Implementation: Update the website and the Panel Member’s Handbook by the end of 2025.

D. Aspects to be Considered in Evaluation

In the Panel Member’s Handbook, Chapter 3.6 *Aspects to be considered in evaluation* will be updated as follows when there are equally influential and respected publication channels in the same field under consideration for level 2:

3.6.6 Publication channels of scholarly societies (formerly “Closed society publication channels”):

- The title will be changed to “*Publication channels of scholarly societies*”.
- If there are equally influential and respected publication channels under consideration for Level 2, preference will be given to those published by scholarly societies. Publication channels that require society membership in order to publish (closed society journals) cannot be accepted at Level

Implementation: Update the website and the Panel Member’s Handbook by the end of 2025.

Discussion:

The secretariat explained the ground for the Change of level 0: The new designation is considered to be more neutral way to communicate in different contexts about identified publication channels that have not been approved to level 1. Level 0 channels are generally associated with the perception that they are of poor quality in one way or another, or have characteristics of predatory journals. In fact, the Level 0 is very heterogeneous. It includes

channels that are properly peer-reviewed but local, new, or located at the interface between scientific and general audience publishing. Originally, JUFO classification did not have level 0 but this name was introduced by the Ministry in the Universities Act in 2014.

It was noted that there has long been a debate for and against maintaining level 3. The following reasons were given by the Steering Group for abandoning the Level 3 and merging it with the Level 2:

- Originally, JUFO classification had only levels 1 and 2. Level 3 was introduced in 2011 because level quotas were based on number journal titles, wherefore in some fields it was felt that level 2 was too broad and further differentiation was needed in form of level 3. Since 2014, level quotas have been calculated based on publication volume, which made levels 2 and 3 more exclusive and difficult to balance with journal quality and size across various subfields. This means that in many panels level 3 involves unhappy compromises.
- From the perspective of panelists and stakeholders, the distinction between levels 2 and 3 is the least important and credible according to surveys of panelists and stakeholders.
- Level 3 treats main field more unequally than combined level 2 and 3.
- Level 3 plays an important role when JUFO classification is misused for assessing individuals, which is not appropriate. In that sense it has been well-founded to reduce the hierarchy of the structure to reduce anxiety related to producing level 3 publications.
- Abandoning level 3 will reduce the work of the panels in the four-yearly update assessment, so more effort can be put on assessment on levels 1 and 2.

It was also mentioned that the removal of level 3 will not effect the current universities' funding model for 2025-2028. Funding for the year 2028 will be calculated in June 2027 based on the combined results of the previous three publication years (2024–2026).

It was clarified that in the new level 2, panels may not include so many series that their combined number of publications (publication volume) would exceed 25 % of the total (number) volume of publications of all level 1 and 2 series in the panel's list. This level quota restriction ensures that level 2 represents only the top of the field, and that not too large a share of publications can be placed on level 2 compared to other panels.

The panel held discussion on changes to the level 1 and level 2 criteria. Particular attention was paid to the new (fourth) criterion in level 2: "The publication channel allows immediate open access." It was clarified that

self-archiving should be allowed or that the article could be made openly available – if necessary, by paying an article processing charge (APC).

5. Preparation for the Spring 2026 evaluation round

In the Spring evaluation round, the panels can classify leading publication channels in different fields into level 2. This level is reassessed every four years.

The scientific community is invited to submit proposals for classification to support the evaluation work of the panels. Members of the scientific community can influence the evaluation of publication channels by submitting proposals for changes to the current levels of publication channels. Proposals should be submitted via the JUFO portal.

The JUFO panelists evaluate the channels within their area of expertise and submit their key proposals for changes (downgrades and upgrades) to level 2 in the JUFO portal by the end of February.

Proposals made by the end of February 2026 will be taken into account in the first phase of the evaluation. In April–May, the panels will prepare a new preliminary level classification proposal, which will be finalized during the fall.

The required data materials for the panels are produced before the panel evaluations, including panel-specific Excel sheets that contain the channels to be evaluated, publication volume data, and statistics by scientific discipline classification.

More information at latest after Panel Chair Meeting of 27.11.2025

The matter was recorded for information.

5. Evaluation of grey area publication channels in the Publication Forum

Within the Publication Forum, there has long been discussion about so-called grey zone journals, which are not outright predatory journals, but which seek to maximise publication output with the least possible investment in editorial work and quality assurance. This business model is designed to maximise financial returns from article processing charges (APCs).

The Secretariat has continued work on clarifying assessment of grey zone channels by developing the [Checklist](#) to support the documentation and coherent consideration of problematic practices.

In line with a decision of the Steering Group, **panels are asked to give their views on whether there is a need to establish an Ethics Expert Group of the Publication Forum to promote coherent identification and treatment**

of grey zone and predatory journals across panels. The group would be composed primarily of panel members, but external domestic and international experts could also be invited if needed.

The task of the Expert Group, in collaboration with the JUFO Secretariat and the panels, would be to:

- Develop the checklist of problematic publishing practices and the documentation of such practices,
- Clarify how problematic practices should be considered in the assessment of channels and in the justifications for decisions, and
- Compile and provide information on problematic practices in publication channels for the panels, the Steering Group, and the research community.

The Expert Group would not evaluate individual publication channels assigned to the panels, but the panels could, if necessary, consult the group on individual cases. The responsibility for classification decisions would remain with the panels.

The JUFO Secretariat would coordinate and facilitate the group's work by providing background information and by relaying observations and experiences received from the research community, for example through the address saalistajat@julkaisuforum.fi.

Discussion:

The unanimous opinion of the panel was that there are no grounds for establishing an Ethics Expert Group. The reasoning behind this position was that the group's experts would be required to have expertise and an in-depth understanding of scientific publishing that exceeds the expertise of even the most experienced researchers. It was also emphasized that responsibility for evaluations would remain with the panels.

The panel also took a critical view of the gray area checklist and its usefulness. It was agreed that the panelists could provide feedback so that the checklist could be developed to better meet the needs of the evaluation work.

6. The use of AI in scientific publishing

In its meeting on May 5, 2025, the Publication Forum Steering Group decided that the secretariat will prepare a study on the use of artificial intelligence (AI) in the scientific publication process. Based on this decision, a [survey](#) has been sent to panelists to assess the utilization of AI in scientific publishing, including related practices, experiences, and perspectives.

The study, which will be based on survey responses, panel discussions, and a literature review, is scheduled for completion in early 2026. All data used in the study, including the content of panel discussions, will be anonymized.

It was agreed that the Panelists may give their comments upon the theme by answering the survey.

1. Other

The final supplementary assessment for 2025 will be carried out in November: For the panel members 1. - 20.11.2025, and the panel chair should confirm the evaluations by 30.11.2025.

2. Closing

The Chair closed the Meeting at 10.05.

Appendix 1

Panel's MinEdu fields

217 Medical engineering

- Medical engineering
- Medical laboratory technology
- Laboratory samples analysis, diagnostic technologies

311 Basic medicine

- Anatomy and morphology
- Human genetics
- Immunology
- Neurosciences, psychophysiology
- Physiology, cytology
- Pathology
- Biophysics
- Tropical medicine, parasitology, infectious diseases, epidemiology

317 Pharmacy

- Pharmacology
- Toxicology
- Medicinal chemistry and pharmaceutical chemistry
- Pharmaceutical technology and industrial pharmacy
- Social pharmacy and pharmacoeconomics
- Pharmaceutical Biology
- Biopharmaceutics and Pharmacokinetics

318 Medicinal biotechnology

- Health-related biotechnology
- Technologies involving the manipulation of cells, tissues, organs or the whole organism
- Technologies involving identifying the functioning of DNA, proteins and enzymes
- Gene-based diagnostics and therapeutics, pharmacogenomics
- Biomaterials
- Medical biotechnology related ethics

List of panel members' expertise

Anna-Liisa Levonen-Harju: Medicine, BIOCHEMISTRY & MOLECULAR BIOLOGY; CELL BIOLOGY; ONCOLOGY; Transcriptional response of cells to stress and its role in diseases

Eero Castrén: Neuroscience; NEUROSCIENCES; PHARMACOLOGY & PHARMACY; PSYCHIATRY; Neuroscience, neuropharmacology, biological psychiatry

Mikko Finnilä: Medicine, ENGINEERING, BIOMEDICAL; MATERIALS SCIENCE; BIOMATERIALS; Musculoskeletal diseases, biomechanics, imaging, biomaterials

Dario Greco: genetics; TOXICOLOGY; PHARMACOLOGY & PHARMACY; MATHEMATICAL & COMPUTATIONAL BIOLOGY; systems biology, systems toxicology, systems pharmacology, predictive pharmacology, bioinformatics, genomics

Reetta Hinttala: Medical cell and molecular biology; CELL BIOLOGY; BIOCHEMISTRY & MOLECULAR BIOLOGY; GENETICS & HEREDITY; biomedical molecular biology, in vitro and in vivo disease models, neurological and multiorgan diseases in children

Pasi Liljeberg: information technology; ENGINEERING, BIOMEDICAL; MEDICAL INFORMATICS; COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; medical technology, information technology

Susanna Miettinen: cell and tissue technology; Stem cells, tissue engineering, cell-biomaterial interactions, 3D bioprinting, in vitro models

Mikko Niemi: Medicine, clinical pharmacology; PHARMACOLOGY & PHARMACY; MEDICAL LABORATORY TECHNOLOGY; MEDICINE, RESEARCH & EXPERIMENTAL; clinical pharmacology, pharmacogenetics, pharmacology

Mataleena Parikka:

Jukka Partanen: genetics; IMMUNOLOGY; GENETICS & HEREDITY; MEDICINE, RESEARCH & EXPERIMENTAL; Transfusion medicine, cell and tissue transplantation; immunogenetics

Eija Pirinen: Molecular medicine; ENDOCRINOLOGY & METABOLISM; BIOCHEMISTRY & MOLECULAR BIOLOGY; MEDICINE, RESEARCH & EXPERIMENTAL; Mitochondrial dysfunction in obesity and metabolic diseases

Emma Raitoharju: Molecular biology/clinical chemistry; GENETICS & HEREDITY; BIOCHEMISTRY & MOLECULAR BIOLOGY; Molecular epidemiology, epigenetics, population study

Timo Roine: Medical physics; NEUROIMAGING; ENGINEERING, BIOMEDICAL; NEUROSCIENCES; Method development: diffusion magnetic imaging, tractography, magnetic stimulation; and clinical applications of methods

Helder Santos: Biomedical engineering; ENGINEERING, BIOMEDICAL; NANOSCIENCE & NANOTECHNOLOGY; MATERIALS SCIENCE, BIOMATERIALS; Nanomedicine, nanotechnology, drug delivery, tissue engineering, biomedical engineering, biomaterials, biomedical technology, biomaterials

Alejandra Sierra Lopez: Biochemistry; NEUROIMAGING; NEUROSCIENCES; PATHOLOGY; MRI validation; microscopy; brain research; imaging; tissue modelling

Pasi Tavi: Physiology; PHYSIOLOGY; BIOPHYSICS; CARDIAC & CARDIOVASCULAR SYSTEMS; Cell physiology

List of engagements

The panel members are asked to disclose their engagements with publication channels in which they have been an editor or a member of the editorial board in the past five years.

Panellist	Publication channel
Jukka Partanen	Frontiers in immunology
Eija Pirinen	Frontiers in Endocrinology
Dario Greco	Scientific Data; Nanomaterials; Journal of Translational Medicine
Emma Raitoharju	Scientific reports
Alejandra Sierra Lopez	Scientific reports
Helder Santos	Smart Materials in Medicine; Nano Select; Drug Delivery and

	Translational Research; Advanced Healthcare Materials; Chemical Society Reviews; VIEW; Precision Nanomedicine; Journal of Controlled Release; Biomedical Technology; Smart Materials in Medicine; Precision Medicine and Engineering
Eero Castrén	Neuropharmacology, Neuronal Signaling, Cellular and molecular Neurobiology, Neurogenesis, Psychiatry Journal.
Anna-Liisa Levonen-Harju	Redox Biology, Free Radical Biology and Medicine

Panel meeting 14.1.2025

Place: House of Science and Letters, room 207 and Teams

Present: Anna-Liisa Levonen-Harju (chair), Eero Castren (from 13.15), Mikko Finnilä, Reetta Hinttala, Pasi Liljeberg, Susanna Miettinen, Jukka Partanen, Eija Pirinen, Emma Raitoharju, Timo Roine, Helder Santos, Alejandra Sierra Lopez, Pasi Tavi

Absent: Mikko Niemi, Dario Greco

Secretariat: Elina Pylvänäinen and Anna-Kaarina Linna

1. Opening

The panel chair opened the meeting at 13.00.

2. Introductions

3. Panel

a. Panel composition

The fields covered in this panel and the fields of expertise of the panel members are listed in appendix 1.

Discussion:

- The panel discussed that the panel could be complemented with an infectious diseases expert. The secretariat will take the proposal to the steering group.

- There is no expert in social pharmacy but it is not necessary to complement the panel at this point.

b. Selecting the vice-chair of the panel

A vice-chair is selected for the panel. The vice-chair stands in for the panel chair when she/he is absent. The vice-chair also has a right to confirm evaluations in the JUFO portal on behalf of the panel chair.

Decision:

- Alejandra Sierra Lopez was selected as a vice-chair of the panel.

4. Orientation to the panel work

The secretariat introduced the Publication Forum, its aims and purpose as well as the evaluation criteria.

5. Level 1 and 0 evaluations in the JUFO portal

The deadline for the first set of level 1 and 0 evaluations is 26.3.2025 for the panel members and the panel chair needs to confirm evaluations at latest on 1.4.2025. More information will be sent by email.

6. Conflicts of interest

The panel members are asked to disclose their engagements with publication channels in which they have been an editor or a member of the editorial board in the past five years. [Please find the list at the end of the document.](#)

7. Other

The secretariat will clarify the legal position of the panel before the autumn meeting.

8. Closing

The panel chair closed the meeting at 15.27.

Appendix 1

Panel's MinEdu fields

217 Medical engineering

- Medical engineering
- Medical laboratory technology
- Laboratory samples analysis, diagnostic technologies

311 Basic medicine

- Anatomy and morphology
- Human genetics
- Immunology

- Neurosciences, psychophysiology
- Physiology, cytology
- Pathology
- Biophysics
- Tropical medicine, parasitology, infectious diseases, epidemiology

317 Pharmacy

- Pharmacology
- Toxicology
- Medicinal chemistry and pharmaceutical chemistry
- Pharmaceutical technology and industrial pharmacy
- Social pharmacy and pharmacoconomics
- Pharmaceutical Biology
- Biopharmaceutics and Pharmacokinetics

318 Medicinal biotechnology

- Health-related biotechnology
- Technologies involving the manipulation of cells, tissues, organs or the whole organism
- Technologies involving identifying the functioning of DNA, proteins and enzymes
- Gene-based diagnostics and therapeutics, pharmacogenomics
- Biomaterials
- Medical biotechnology related ethics

List of panel members' expertise

Anna-Liisa Levonen-Harju: Medicine, BIOCHEMISTRY & MOLECULAR BIOLOGY; CELL BIOLOGY; ONCOLOGY; Transcriptional response of cells to stress and its role in diseases

Eero Castrén: Neuroscience; NEUROSCIENCES; PHARMACOLOGY & PHARMACY; PSYCHIATRY; Neuroscience, neuropharmacology, biological psychiatry

Mikko Finnilä: Medicine, ENGINEERING, BIOMEDICAL; MATERIALS SCIENCE; BIOMATERIALS; Musculoskeletal diseases, biomechanics, imaging, biomaterials

Dario Greco: genetics; TOXICOLOGY; PHARMACOLOGY & PHARMACY; MATHEMATICAL & COMPUTATIONAL BIOLOGY; systems biology, systems toxicology, systems pharmacology, predictive pharmacology, bioinformatics, genomics

Reetta Hinttala: Medical cell and molecular biology; CELL BIOLOGY; BIOCHEMISTRY & MOLECULAR BIOLOGY; GENETICS & HEREDITY; biomedical

molecular biology, in vitro and in vivo disease models, neurological and multiorgan diseases in children

Pasi Liljeberg: information technology; ENGINEERING, BIOMEDICAL; MEDICAL INFORMATICS; COMPUTER SCIENCE, INTERDISCIPLINARY APPLICATIONS; medical technology, information technology

Susanna Miettinen: cell and tissue technology; Stem cells, tissue engineering, cell-biomaterial interactions, 3D bioprinting, in vitro models

Mikko Niemi: Medicine, clinical pharmacology; PHARMACOLOGY & PHARMACY; MEDICAL LABORATORY TECHNOLOGY; MEDICINE, RESEARCH & EXPERIMENTAL; clinical pharmacology, pharmacogenetics, pharmacology

Jukka Partanen: genetics; IMMUNOLOGY; GENETICS & HEREDITY; MEDICINE, RESEARCH & EXPERIMENTAL; Transfusion medicine, cell and tissue transplantation; immunogenetics

Eija Pirinen: Molecular medicine; ENDOCRINOLOGY & METABOLISM; BIOCHEMISTRY & MOLECULAR BIOLOGY; MEDICINE, RESEARCH & EXPERIMENTAL; Mitochondrial dysfunction in obesity and metabolic diseases

Emma Raitoharju: Molecular biology/clinical chemistry; GENETICS & HEREDITY; BIOCHEMISTRY & MOLECULAR BIOLOGY; Molecular epidemiology, epigenetics, population study

Timo Roine: Medical physics; NEUROIMAGING; ENGINEERING, BIOMEDICAL; NEUROSCIENCES; Method development: diffusion magnetic imaging, tractography, magnetic stimulation; and clinical applications of methods

Helder Santos: Biomedical engineering; ENGINEERING, BIOMEDICAL; NANOSCIENCE & NANOTECHNOLOGY; MATERIALS SCIENCE, BIOMATERIALS; Nanomedicine, nanotechnology, drug delivery, tissue engineering, biomedical engineering, biomaterials, biomedical technology, biomaterials

Alejandra Sierra Lopez: Biochemistry; NEUROIMAGING; NEUROSCIENCES; PATHOLOGY; MRI validation; microscopy; brain research; imaging; tissue modelling

Pasi Tavi: Physiology; PHYSIOLOGY; BIOPHYSICS; CARDIAC & CARDIOVASCULAR SYSTEMS; Cell physiology

List of engagements

The panel members are asked to disclose their engagements with publication channels in which they have been an editor or a member of the editorial board in the past five years.

Panellist	Publication channel
Jukka Partanen	Frontiers in immunology
Eija Pirinen	Frontiers in Endocrinology
Dario Greco	Scientific Data; Nanomaterials; Journal of Translational Medicine
Emma Raitoharju	Scientific reports
Alejandra Sierra Lopez	Scientific reports
Helder Santos	Smart Materials in Medicine; Nano Select; Drug Delivery and Translational Research; Advanced Healthcare Materials; Chemical Society Reviews; VIEW; Precision Nanomedicine; Journal of Controlled Release; Biomedical Technology; Smart Materials in Medicine; Precision Medicine and Engineering
Eero Castrén	Neuropharmacology, Neuronal Signaling, Cellular and molecular Neurobiology, Neurogenesis, Psychiatry Journal.
Anna-Liisa Levonen-Harju	Redox Biology, Free Radical Biology and Medicine